Instrument Inactif

Autres langues CEL-SCI Corporation Nyse

Actions

US1508374097

Cours en clôture Nyse Autres places de cotation
- ^USD	-

15/05	CEL-SCI Corporation annonce ses résultats pour le deuxième trimestre et le semestre clos le 31 mars 2024	CI
08/05	Cel-Sci obtient l'autorisation de la FDA américaine de procéder à une étude de confirmation pour son médicament contre le cancer Multikine	MT

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

CEL-SCI Presents Head and Neck Cancer Data at Iddst Annual Congress in Budapest, Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population	19/06
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population	18/06
CEL-SCI Corporation (von First Berlin Equity Research GmbH...	11/06
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor	06/06
Cel-Sci: Fiscal Q2 Earnings Snapshot	16/05
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results	16/05
CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	15/05
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head and Neck Cancer	09/05
Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine	08/05
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer	08/05
CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine	08/05
CEL-SCI Corporation Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer	08/05
CEL-SCI Appoints Mario Gobbo to Its Board of Directors	23/04
CEL-SCI Corporation Appoints Mario Gobbo as Board of Directors	23/04
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology	19/03
CEL-SCI Corporation Issues Letter to Shareholders	06/03
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results	15/02
Cel-Sci: Fiscal Q1 Earnings Snapshot	14/02
CEL-SCI Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023	14/02
CEL-SCI Corporation (von First Berlin Equity Research GmbH...	14/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues CEL-SCI Corporation Nyse

Actions

US1508374097

Autres langues

Filtres